<DOC>
	<DOCNO>NCT02109185</DOCNO>
	<brief_summary>The study compare safety efficacy generic mometasone nasal spray reference list drug treatment seasonal allergic rhinitis . Additionally test reference formulation test superiority placebo nasal spray .</brief_summary>
	<brief_title>A Comparison Mometasone Nasal Spray , Nasonex Nasal Spray , Nasonex Nasal Spray Suspension , &amp; Placebo Treatment Seasonal Allergies Safety , Efficacy , &amp; Superiority 1520 Male &amp; Female Volunteers</brief_title>
	<detailed_description>The study compare safety , efficacy , superiority generic mometasone nasal spray reference product placebo treatment seasonal allergic rhinitis . This protocol describe randomize , double-blind , placebo-controlled , 4- treatment group parallel study 14 day duration precede single blind 7-day placebo run-in period investigate clinical equivalence Mylan 's Mometasone Furoate Monohydrate Nasal Spray , 50 ug per actuation Merck Sharp &amp; Dohme 's ( MSD ) Nasonex® Nasal Spray , 50 ug per actuation MSD EU 's Nasonex® Nasal Spray Suspension , 50 ug per actuation . In addition , superiority test reference product placebo assess . Prior randomization one 4 study group , subject 7-day placebo run-in period . Each subject receive one follow treatment : Mylan 's Mometasone Furoate Nasal Spray 50 μg/actuation ( 2 actuation per nostril per day ) ; Merck-US Nasonex® Nasal Spray 50 μg/actuation ( 2 actuation per nostril per day ) ; Merck-EU 's Nasonex® Nasal Spray Suspension 50 μg/actuation ( 2 actuation per nostril per day ) ; Mylan 's Placebo Nasal Spray 50 μL/actuation ( 2 actuation per nostril per day ) . Active treatment 14 day duration . Reflective total nasal score ( rTNSS ) collect every 12 hour 21 day .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>1 . Age : 12 year age old . 2 . Signed informed consent form . For patient age majority , parent legal guardian sign consent form child require sign patient `` assent '' form . 3 . Sex : Male and/or nonpregnant , nonlactating female . All woman childbearing potential must negative serum pregnancy test perform within 21 day prior start study must use medically acceptable form birth control . Women consider childbearing potential one follow report documented medical history : postmenopausal spontaneous amenorrhea least six month serum FSH level &gt; 40mIU/ml , bilateral oophorectomy without hysterectomy absence bleed least 6 month , total hysterectomy absence bleed least 3 month . 4 . History seasonal allergic rhinitis least 2 year duration 5 . Positive response skin allergen test relevant seasonal allergen ( e.g . grass/tree/ragweed ) sit geographical area within 14 month time study entry . Wheal size must great equal ( ≥ ) 5 mm large diameter diluent control via prick test great equal 7 mm large diameter diluent control via intradermal test . 6 . Clinically active status ( symptomatic ) screen baseline . The total nasal symptom score great equal 6 03 symptom scale score least 2 ( moderate severity ) nasal congestion/stuffiness one nasal symptom score ( rhinnorea , nasal itching , sneeze ) , overall disease rating moderate severe ( e.g . total score six great ) . 7 . Weight : Age appropriate weight . BMI exceed 40 kg/m2 8 . Tobacco Use : nontobacco use least 3 month prior study initiation . 9 . Capable provide informed consent assent . 10 . All subject judge Principal Investigator Medical SubInvestigator otherwise normal healthy free clinically significant disease except sign symptom rhinoconjunctivitis would interfere study schedule evaluation SAR prestudy medical evaluation perform within 21 day initial dose study medication include : 1. normal nonclinically significant physical examination include nasal passage evaluation , include vital sign ( pulse , temperature , respiration rate , blood pressure ) 2. within normal limit nonclinically significant laboratory evaluation result ( unless otherwise specify ) follow test : Serum Chemistries Sodium Albumin Blood urea nitrogen ( BUN ) Potassium Uric Acid Aspartate aminotransferase ( AST ) Chloride Iron Alanine aminotransferase ( ALT ) Calcium *Total Cholesterol* Alkaline Phosphatase Creatinine *Glucose* Phosphate Total Protein *Triglycerides* Total Bilirubin Fasting nonfasting may perform base clinical judgment Hematology Platelet Count White blood cell count w/differential Hemoglobin Hematocrit Red Blood Cell count Urinalysis Protein pH Specific Gravity Appearance Microscopic Examination ( perform urine dipstick positive ) 3. normal nonclinically significant 12lead ECG 4. negative urine drug screen include amphetamine , barbiturate , benzodiazepine , cannabinoid ( marijuana ) , methadone , cocaine , opiates , phencyclidine unless legal prescribed allow state/federal law . 5 . Additional test examination may perform , judge necessary Principal Investigator Medical SubInvestigator . 1 . Institutionalized subject . 2 . Individuals rTNSS score 6 great start placebo runin period randomization day ( i.e . Study Day 8 ) long meet requirement ( i.e . score &lt; 6 ) prior randomization , score less 2 Stuffiness/Congestion , score less 2 3 remain Nasal Symptoms result discontinuation subject study subject receive randomize treatment . The rTNSS score assessed randomization day ( i.e . Study Day 8 ) average score precede 7 scoring time point . For example , randomization occurs Day 8 , average total score placebo runin phase include rTNSS score Study Day 5 ( AM &amp; PM ) , Study Day 6 ( AM &amp; PM ) , Study Day 7 ( AM &amp; PM ) , Study Day 8 ( AM ) . 3 . Females pregnant nursing . 4 . History alcohol and/or drug abuse within 1 year subject randomization . 5 . Medications : *All routinely use ( e.g . daily ) concomitant medication take comorbidity ( i.e . hypertension , high triglyceride , diabetes , etc ) document . Subjects receive concomitant medication stable dos medication ( defined change dose least 3 month dose anticipate change study ) . *Subject dependent nasal , oral , ocular decongestant , antiinflammatory agent ; determine principal investigator , diagnosis rhinitis medicamentosa . *Subjects tolerate nasal spray . *Use intranasal systemic first generation antihistamine , leukotriene receptor antagonist ( i.e . montelukast ) nasal decongestant within 3 day enrollment . *Use intranasal cromolyn within 14 day enrollment . *Use intranasal systemic secondgeneration antihistamine ( e.g . fexofenadine , loratadine , desloratadine , cetirizine ) within 10 day enrollment . *Use tricyclic antidepressant within 30 day enrollment . *Use ophthalmic steroid within 14 day nasal , inhale , systemic steroid within 30 day study start . Super high potency topical steroid use study . The use low potency topical corticosteroid allow ( e.g . overthecounter 1 % hydrocortisone ) . *Use chronic medication could affect course seasonal allergic rhinitis . 6 . Diseases Subjects upper respiratory tract sinus infection require antibiotic therapy within thirty day day enrollment , viral upper respiratory tract infection within 30 day prior screen visit . History recurrent sinusitis chronic purulent postnasal drip History significant cardiovascular , hepatic , renal , pulmonary , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychological , musculoskeletal disease , malignancies significant medical illness , judgement principal investigator could interfere study require medical treatment would interfere study . Clinical evidence large nasal polyp , mark septal deviation , nasal structural abnormality may significantly interfere nasal airflow , determine principal investigator . History asthma previous two year require chronic therapy inhale systemic corticosteroid . Occasional acute mild exercise induce asthma allowable condition treatment attack restrict βagonists . Recent exposure ( within 30 day ) risk expose chicken pox measles . Previous seasonal allergic rhinitis perennial allergic rhinitis proven unresponsive steroid therapy . Subjects infectious rhinitis atrophic rhinitis . History anaphylaxis and/or severe local reaction ( ) skin testing , determine Principal Investigator Medical Subinvestigator . Symptoms common cold upper respiratory infection acute illness screen baseline visit . Treatment oral Candidiasis within 30 day start study current oral Candidiasis infection History posterior subcapsular cataract . History tuberculosis , presence uncontrolled glaucoma , cataract , ocular herpes simplex , conjunctivitis eye infection relate diagnosis seasonal allergic rhinitis . Presence untreated fungal , bacterial , systemic viral infection within previous 30 day . 7 . Recent history nasal septal surgery , nasal septal perforation ( ulceration ) recent nasal injury completely heal . 8 . Any reason , opinion Principal Investigator Medical SubInvestigator , would prevent subject safely participate study . 9 . Travel outside geographical region pollen ( local area ) 2 consecutive day 3 day total throughout trial . 10 . Anticipation clinically significant symptom due perennial allergen ( e.g . dust mite , mold , animal dander ) prior anticipate start relevant seasonal allergy season . In word anticipate flare perennial allergy symptom immediately prior seasonal allergic rhinitis flare . 11 . Previous participation study , patient member investigational study site staff member family investigational study site staff . 12 . Not stable dose immunotherapy least 3 month prior randomization trial . 13 . Desensitization therapy seasonal allergen responsible subject 's allergic rhinitis initiate change within previous six month . 14 . Subjects receive investigational drug within 30 day prior initial dose study medication . 15 . History allergy/hypersensitivity mometasone , relate product ( i.e corticosteroid ) , inactive ingredient .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>seasonal allergic rhinitis</keyword>
	<keyword>grass/tree/ragweed allergy</keyword>
	<keyword>nasal congestion/stuffiness</keyword>
	<keyword>rhinnorea</keyword>
	<keyword>nasal itch</keyword>
	<keyword>sneeze</keyword>
</DOC>